Inhibition of HIV-1 reactivation by a telomerase-derived peptide in a HSP90-dependent manner

Hong Kim1, Myung-Soo Choi2, Kyung-Soo Inn2 & Bum-Joon Kim1

A peptide vaccine designed to induce T-cell immunity to telomerase, GV1001, has been shown to modulate cellular signaling pathways and confer a direct anti-cancer effect through the interaction with heat shock protein (HSP) 90 and 70. Here, we have found that GV1001 can modulate transactivation protein-mediated human immunodeficiency virus (HIV)-1 transactivation in an HSP90-dependent manner. GV1001 treatment resulted in significant suppression of HIV-1 replication and rescue of infected cells from death by HIV-1. Transactivation of HIV-long terminal repeat (LTR) was inhibited by GV1001, indicating that GV1001 suppressed the transcription from proviral HIV DNA. The anti-HIV-1 activity of GV1001 was completely abrogated by an HSP90-neutralizing antibody, indicating that the antiviral activity depends on HSP90. Further mechanistic studies revealed that GV1001 suppresses basal NF-κB activation, which is required for HIV-1 LTR transactivation in an HSP90-dependent manner. Inhibition of LTR transactivation by GV1001 suggests its potential to suppress HIV-1 reactivation from latency. Indeed, PMA-mediated reactivation of HIV-1 from latent infected cells was suppressed by GV1001. The results suggest the potential therapeutic use of GV1001, a peptide proven to be safe for human use, as an anti-HIV-1 agent to suppress the reactivation from latently infected cells.

Human reverse transcriptase subunit of telomerase (hTERT) is highly expressed in various cancer tissues and it has been considered as an attractive target for the development of effective cancer vaccines1. A peptide vaccine, encompassing the 16mer MHC class II epitope (611-EARPALLTSRLRFIPK-626) of hTERT, GV1001, has been developed as a therapeutic vaccine to induce T-cell immune responses2. Several phase I/II clinical trials have confirmed the safety and capability of inducing specific T-cell responses in patients with pancreatic cancer, non-small cell lung cancer (NSCLC), melanoma and hepatocellular carcinoma3–7. In addition, a clear positive correlation between induced immune responses and prolonged survival of advanced pancreatic cancer patients has been shown in a phase II study3.

In previous studies, we have shown that GV1001 interacts with extracellular heat shock protein 90 (HSP90) and penetrates into the cytoplasm of cells8. Moreover, GV1001 exerted a strong anti-cancer effect through the interaction with HSP90 under hypoxic conditions by modulating the HIF-1α-VEGF signaling axis9. These studies indicate that GV1001 can regulate intracellular signaling pathways through the interaction with HSP90.

HSPs are molecular chaperones, and they play crucial roles in maintaining protein homeostasis and cell homeostasis, particularly under stress conditions10. HSP90 has been associated with several pathological conditions such as cancer, atherosclerosis and virus infection11–14. The HSP90 client list includes numerous proteins related to tumorigenesis, invasiveness and metastasis15. Thus, HSP90 has emerged as a promising target for cancer therapeutics, and several HSP90 inhibitors have been developed and are undergoing clinical trials16. Interestingly, secreted HSP90 and cell surface HSP90 have been observed in cancer cells, and these extracellular HSP90 (eHSP90) proteins promote cancer growth and angiogenesis17,18. Noncancerous cells also produce eHSP90 under various environmental conditions, including heat, hypoxia and starvation17. eHSP90 plays distinct functions from those of intracellular HSP90, and it can regulate cell signaling pathways by interacting with various cell surface proteins17. Upon virus infection, robust production of viral proteins also requires HSP functions, and the list of viruses suppressed by HSP90 inhibitors continues to grow19. Recent studies have shown that human immune deficiency virus-1 (HIV-1) infection also resulted in increased expression of HSP90 in mononuclear cells20.

1Department of Microbiology and Immunology, Liver Research Institute, Biomedical Sciences and SNUMRC, College of Medicine, Seoul National University, Seoul, Korea. 2Department of Pharmaceutical Science, College of Pharmacy, Kyung Hee University, Seoul, Korea. Correspondence and requests for materials should be addressed to K.-S.I. (email: innks@khu.ac.kr) or B.-J.K. (email: kbumjoon@snu.ac.kr)
cells and T-cells. Indeed, HSP90 plays a pivotal role in HIV replication by acting at multiple steps of the life cycle of the virus. HSP90 involvement in HIV viral transcription and HIV replication in acutely infected cells was suppressed by HSP90 inhibitors. Moreover, HSP90 regulates HIV reactivation from latency by modulating NF-κB signaling.

Considering that GV1001 interacts with HSP90 and modulates cell signaling, we explored the possible antiviral role of GV1001 against HIV-1 in the current study.

**Results**

**GV1001 suppresses HIV-1 replication.** Prior to examination of the role of GV1001, we analyzed the cell cytotoxicity of GV1001 to exclude the possibility that GV1001 affects the replication of HIV-1 due to its nonspecific cell cytotoxicity. GV1001 does not exert significant cytotoxic activity against MT-4, IG5 and ACH-2 cells up to 25 μM (Fig. 1A). First, the anti-HIV-1 activity of GV1001 was determined by analyzing its effect on HIV-1 (pBR_HIV-1-M-NL4-3_IRES_eGFP) replication in MT-4 cells. As determined by p24 ELISA, production of viral particles in MT-4 cells was significantly inhibited by GV1001 in a dose-dependent manner, and the mean 50% inhibitory concentration (IC50) value was approximately 0.85 μM (Fig. 1B). Additionally, eGFP production, which depends on the activation of HIV-1 Nef expression, was also diminished by treatment with GV1001 (Fig. 1C). Inhibition of HIV-1 viral RNA synthesis and p24 production by GV1001 in HIV-1-infected PBMCs was confirmed by determining the levels of viral genomic RNA and p24 protein in the supernatants (Fig. 1D). A peptide derived from HBV polymerase did not exert any significant effect on HIV virion production and eGFP production, indicating that the anti-HIV function of GV1001 is not non-specific (Fig. S1).

In line with the suppression of HIV-1 replication by GV1001, the latter displayed a cell protective effect on HIV-1-infected MT-4 cells. As depicted in Fig. 1E,F, AZT and GV1001 showed a significant cell protective effect in a dose-dependent manner. Similar to AZT, 5 μM GV1001 was sufficient to confer almost 100% cell protection from HIV-1-mediated cell death. Its cell protective effect was inversely correlated with a decreased supernatant p24 level, suggesting that GV1001 can protect cells by suppressing viral replication. Furthermore, GV1001 treatment resulted in decreased intracellular HIV viral genomic RNA, p24 protein synthesis and eGFP expression in human peripheral blood mononuclear cells (PBMCs) infected with HIV-1 (Figs 1G and S2).

![Figure 1](image-url)
HIV-1 transcription is inhibited by GV1001. Considering that eGFP production from the HIV-1 genome is under the same control as Nef, decreased expression of eGFP in HIV-1-infected cells by GV1001 indicates the suppression of HIV-1 transcription by GV1001 (Fig. 1C). To further delineate the underlying mechanism of HIV-1 inhibition by GV1001, a time-of-addition (TOA) study was performed using GV1001 and several anti-HIV drugs covering different stages of HIV replication. The results of each reagent in the TOA assay have shown that the inhibition of HIV replication was well represented to a time point corresponding to the occurrence of the replication step targeted by the drugs, and GV1001 started to lose its activity at the time point between 11 hours and 13 hours after HIV-1 infection (Fig. 2A). Analysis of eGFP expression confirmed that the inhibitory activity of GV1001 is weakened when treated for 12 hours after infection (Fig. 2B). According to the typical result from a time-of-addition assay, the viral transcription of HIV from the integrated HIV genome occurs from 11 to 13 hours after infection. Thus, this result suggests that the mode of action of GV1001 in the MT-4 cells infected with HIV is to inhibit HIV proliferation through suppressing the transcription activity. Furthermore, GV1001 efficiently suppressed the production of the viral mRNA of HIV-1 when cells were treated with it for up to 9 hours after infection, while it lost its activity to lower the viral mRNA when it was treated 13 hours after infection (Fig. 2C). At the same time, there was no significant change in the housekeeping host GAPDH mRNA synthesis, suggesting that GV1001 specifically regulates HIV-1 viral transcription.

GV1001 inhibits Tat-dependent HIV-1 transcription. HIV-1 transactivating protein (Tat) enhances HIV-1 transcription through the interaction with the tat-transactivation-responsive region (TAR). Because GV1001 is likely to specifically regulate HIV-1 transcription, we have tested whether GV1001 affects the transactivating role of HIV-1 Tat. We exploited 1G5, which is a Jurkat derivative cell line containing a stably integrated HIV-LTR-luciferase construct. After 1G5 cells were infected with HIV-1 or transduced with a tat-retroviral vector (pSV2tat72) in the presence of AZT and GV1001, luciferase activity was analyzed. 1G5 cells infected with HIV-1 showed a dramatic increase in luciferase activity, and AZT or GV1001 treatment significantly reduced the effect of HIV-1 infection on HIV-LTR-Luciferase activity by fivefold (Fig. 3A). Consistently, GV1001 suppressed the activation of HIV-LTR luciferase activity induced by ectopic expression of Tat, suggesting its capability to regulate the transactivating role of tat during HIV-1 infection (Fig. 3B).

GV1001 suppresses the reactivation of HIV-1 from latency. Given that GV1001 regulates Tat-dependent transcriptional activity, the role of GV1001 in HIV-1 reactivation was investigated. ACH-2 cells, a human T cell line encompassing a single copy of proviral HIV-1 DNA, were treated with PMA along with vehicle, AZT or GV1001. PMA treatment significantly increased the supernatant p24 level, and GV1001 almost abolished the effect, whereas AZT did not change the effect of PMA (Fig. 4A). This result indicates that GV1001 suppresses the PMA-induced HIV-1 reactivation and production of viral particles. Similarly, HIV-1 viral RNA genome levels
were also significantly decreased in the supernatants from PMA-treated cells following treatment with GV1001 in a dose-dependent manner, supporting the previous data (Fig. 4B).

Figure 3. Suppression of Tat-dependent HIV-1 transcription by GV1001. (A) 1G5 cells, which harbor a stably integrated HIV-LTR-luciferase construct, were infected with HIV-1, followed by treatment with DMSO, AZT or GV1001. Four days after infection, cell lysates were subjected to luciferase assay to analyze the transactivation of HIV-LTR. (B) 1G5 cells were transfected with the Tat plasmid. Twelve hours after transfection, cells were treated with vehicle (DMSO), AZT or GV1001 as indicated. Four days after transfection, HIV-LTR transactivation was analyzed by the luciferase assay. Data represent means ± SD. ***p < 0.001.

Figure 4. Suppressive effect of GV1001 on reactivation of HIV-1 from latency. (A) ACH-2 cells, which are latently infected with HIV-1, were stimulated with PMA (50 nM) to induce the reactivation of HIV-1 for 1 hour. Next, cells were treated with DMSO, AZT or GV1001 for 24 hours. The level of produced viral particles in the supernatants was determined by p24 ELISA. (B) ACH-2 cells were treated with PMA followed by treatment with increasing concentrations of AZT or GV1001 as in (A). The levels of produced viral particles were determined by measuring the amount of viral genomic RNAs using RT-qPCR. Data represent means ± SD. ***p < 0.001 versus DMSO control.

Anti-HIV-1 activity of GV1001 is HSP90-dependent. Next, it has been examined whether GV1001 modulates HIV-1 replication via its interaction with HSPs. Surprisingly, GV1001-mediated suppression of HIV-1 production in MT-4 cells was completely restored by treatment with an anti-HSP90 neutralizing antibody, while AZT-mediated suppression was not affected at all (Fig. 5A). Anti-HSP70-neutralizing antibody treatment resulted in partial restoration, and an isotype control anti-GAPDH antibody showed no significant effect (Fig. 5A). Suppression of eGFP expression, which depends on HIV-1 transcriptional activity by GV1001, was also reverted by the anti-HSP90 antibody, whereas the effect of AZT was not affected (Fig. 5B,C). These results show that GV1001 can regulate HIV-1 transcriptional activity through its interaction with HSP90.
GV1001 suppresses basal NF-κB transcriptional activity. Given that NF-κB can trigger HIV transcription by interacting with HIV-LTR, we tested the hypothesis that GV1001 modulates NF-κB activity in an HSP90-related manner to regulate HIV-1 transcriptional activity. Treatment with GV1001 resulted in a dramatic decrease in basal NF-κB activity regardless of HIV-1 infection in MT-4 cells (Fig. 6A). By contrast, AZT showed no significant effect on NF-κB activity in MT-4 cells. AZT showed a moderate suppressive effect in MT-4 cells infected with HIV-1, a finding that might be due to the low level of HIV replication (Fig. 6A). The suppressive effect on basal NF-κB activity of GV1001 was further confirmed by EMSA. As shown in Fig. 6B, GV1001-treated cells showed clear reduction of p65 NF-κB activation, indicating that GV1001 suppresses the basal level of NF-κB DNA binding in the nucleus. GV1001 treatment also leads to reduced NF-κB (p65) phosphorylation, indicating that GV1001 suppresses the cytosolic activation of NF-κB and subsequent nuclear translocation (Fig. 6C). A similar result was obtained from ACH-2 cells latently infected with HIV-1 (Fig. 6C). As expected, treatment with GV1001 resulted in decreased nuclear localization of NF-κB (p65) in PMA-treated ACH-2 cells compared with DMSO-treated control cells (Fig. 6D). Because we have shown that the anti-HIV effect of V1001 depends on HSP90, we tested whether the NF-κB suppressive effect is dependent on HSP90. Consistent with the anti-HIV activity data, the NF-κB suppressive activity of GV1001 was also completely reversed by treatment with an HSP90 blocking antibody or HSP90 inhibitor, while treatment with an anti-GAPDH antibody showed no significant effect (Fig. 7).

Discussion
Previously, we have shown that GV1001 interacts with extracellular HSP90 and is internalized into cells. In Hepatitis C virus (HCV)-infected cells, GV1001 suppressed the replication of HCV through the interaction with HSP90.8,25 Given that HSP90 plays crucial roles in the HIV-1 life cycle and that GV1001 interacts with HSP90, it was very tempting to examine the possible antiviral activity of GV1001 against HIV-1. To our surprise, GV1001 displayed potent anti-HIV-1 activity. Our Time-of-addition study suggested that GV1001 suppresses the replication of HIV-1 at the level of viral transcription. Indeed, GV1001 suppressed Tat-dependent transcriptional activity and decreased the level of HIV-1 RNA (Figs 2C and 3A,B). Inhibition of Tat-dependent viral transcription by GV1001 suggests that it might be able to suppress the reactivation of latently infected HIV-1. Despite the successful suppression of HIV replication by highly active antiretroviral therapy (HAART), current therapeutic...
strategies cannot eradicate latently infected HIV-1, and reactivation of the virus is a cause of treatment failure. Because GV1001 has already been proven to be safe by several clinical trials, it is worthwhile to further evaluate

Figure 6. Inhibition of basal NF-κB activation by GV1001. (A) MT-4 cells were transfected with NF-κB firefly luciferase and CMV-promoter Renilla luciferase reporter plasmids. Next, cells were infected with HIV-1 (1 × 10^6 CCID50) and treated with the designated compounds for 24 hours, followed by dual-luciferase assay. Data represent means ± SD. **p < 0.001 versus DMSO control. (B) MT-4 cells were infected with HIV-1 and treated with DMSO, AZT or GV1001 as indicated. Twenty-four hours after infection, the nuclear fractions were extracted and subjected to EMSA assay. NF-κB and AP-2 competitor oligomers were used to confirm the specificity. (C) MT-4 cells and ACH-2 cells were treated with DMSO, AZT (5 nM) or GV1001 (10 μM) for 1 hour. Cell lysates were subjected to immunoblotting analysis using indicated antibodies. (D) ACH-2 cells were stimulated with TNF-α (30 ng/ml) or PMA (50 nM) for 1 hour and treated with DMSO, AZT or GV1001 for 24 hours. Next, cells were stained with anti-p65 NF-κB antibody and Alexa Flour 594-conjugated secondary antibody after permeabilization. After brief DAPI nuclear staining, cells were observed by confocal microscopy. Colocalization coefficient of p65 and DAPI was determined by Manders’ overlap coefficient analysis using NIS-Elements Ver 4.2 image software. Scale bar, 10 μm. Data represent means ± SD. ***p < 0.001 versus ACH-2 control.
cellular HSP90 plays a crucial role in HIV reactivation by directly regulating NF-κB transactivation. Although the underlying molecular mechanisms of NF-κB signaling and HIV-LTR activation are currently underway. We showed that treatment with GV1001 resulted in suppression NF-κB activation and subsequent down-regulation of TAT-dependent transcription. Moreover, suppression of NF-κB activation by GV1001 was restored by the treatment with an anti-HSP90 antibody.

Collectively, we show that GV1001 suppresses the basal level of NF-κB activity, leading to the suppression of HIV-LTR transactivation. Although the underlying molecular mechanisms of NF-κB suppression remain elusive, the results clearly indicate that HSP90 is implicated in the activity. An elegant previous study showed that intracellular HSP90 plays a crucial role in HIV reactivation by directly regulating NF-κB activity in T-cells and HIV-LTR activation. Indeed, recent studies have shown that extracellular HSP90 can enhance the NF-κB signaling pathway29. NF-κB can trigger HIV transcription by interacting with NF-κB binding sites within HIV-LTR, and it enhances TAT-mediated LTR transactivation30. In addition, Tat can directly activate NF-κB31. We showed that treatment with GV1001 resulted in suppression NF-κB activation and subsequent down-regulation of TAT-dependent transcription. Moreover, suppression of NF-κB activation by GV1001 was restored by the treatment with an anti-HSP90 antibody.

Materials and Methods

Peptides and Reagents. A 16-amino acid human telomerase reverse transcriptase (hTERT)-derived peptide, GV1001, and a 13-amino acid HBV polymerase derived control peptide (Pol-LQHGRAKFQST) were synthesized and characterized as described previously34. T-20, Raltegravir, Flavopiridol, and Rinonavir were obtained from the NIH/AIDS Research and Reference Reagent Program (NIH, Bethesda, MD). Azidothymidine (3-Azido-3-deoxythymidine, AZT) was purchased from Sigma-Aldrich (St. Louis, MO). Antibodies against HSP90 (#4877S), phospho-NF-κB (p65, #2859S), IκB (IκBα, #8418S) and phospho-IκB (IκBα, #8489S) were purchased from Cell Signaling (Danvers, MA), and anti-p24 antibody (Ab9071) was bought from Abcam (Abcam, Cambridge, MA). Antibodies against HSP70 (sc32239), GFP (sc81045), GAPDH (sc25778) and NF-κB (p65, sc372) were purchased from Santa Cruz Biotechnology (Santa Cruz, Dallas, TX).

Cells, plasmids and virus. The human T-cell leukemia cell line MT-4, the ACH-2 cell line latently infected with HIV-1, and a Jurkat derivative 1G5 cell line containing a stably integrated HIV-LTR-luciferase construct were obtained from the NIH/AIDS Research and Reference Reagent Program. The pSV2tat2 plasmid (Cat. No. 294, provided by Dr. Alan Frankel) producing Tat protein (residues 1–72) was obtained from the NIH/AIDS Research and Reference Reagent Program35. To produce HIV-1, 293FT cells were transfected with the pBR-HIV-1_M_NL4-3_IRES_eGFP vector which co-expresses Nef and enhanced green fluorescence protein (eGFP) from a single bicistronic RNA (Cat. No. DS441, provided by Dr. Daniel Sauter and Dr. Frank Kirchhoff) using Lipofectamine 2000 reagent (Life Technologies)36. Forty-eight hours after transfection, virus-containing medium was harvested and the viral titer was determined using p24 ELISA (ABL, city, MD). For amplification of infectious...
HIV-1, MT-4 cells were infected with generated HIV-1 (MOI = 0.5) for 48 hours. After brief centrifugation, the supernatant was filtered and subjected to titration using p24 ELISA.

**Anti-viral effect assay.** To evaluate the anti-HIV-1 effect of GV1001, the cell-based anti-viral effect assay was performed. MT-4 cells (4 × 10^5 cells) were infected with HIV-1 (4 × 10^5 CCID₅₀) for 1 hour. After washing, infected cells were seeded and treated with GV1001 or anti-HIV-1 drugs. After 2 days of incubation, the images of MT-4 cells expressing EGFP were obtained using fluorescence microscopy. The relative GFP intensity was determined using ImageJ software program (National Institutes of Health) in pixels per area. The collected supernatant was subjected to p24 ELISA or RNA extraction for reverse transcription-quantitative polymerase chain reaction (RT-qPCR) to determine the extracellular viral amount. The cell pellets were used for the cell viability assay. To examine the role of HSP90 in the antiviral action of GV1001, MT-4 cells were infected with HIV for 1 hour and treated with anti-HSP70 (10 ng) or anti-HSP90 (10 ng). HIV-LTR-dependent synthesis of eGFP was also confirmed by immunoblotting using an anti-GFP antibody with cell lysates. For antiviral assays using normal human PBMCs, separated PBMCs were activated with 1 μg/ml phytohemagglutinin (PHA) (Sigma-Aldrich, St. Louis, MO) for 3 days in the presence of IL-2 (100 U/ml) (PEPROTECH, Rocky Hill, NJ). PHA-stimulated PBMCs were infected with HIV-1 at a multiplicity of infection (MOI) of 0.1 and treated with indicated reagents for 3 days and subjected to fluorescent microscopy. To determine the viral replication in PBMCs, intracellular viral RNAs were isolated and analyzed by RT-qPCR as described below. All studies were performed following protocols approved by the Seoul National University Hospital Institutional Review Board (IRB, No 1605-056-761).

**Cell cytotoxicity assay.** MT-4, 1G5 or ACH-2 cells were seeded (1 × 10⁴ cells/well) in 96-well microplates and incubated with increasing concentrations of GV1001 for 5 days. Cell viability was determined using CellTiter96 kit (Promega, WI). To analyze the cell protective effect of GV1001 from HIV-1-induced cell death, MT-4 cells (1 × 10⁴ cells) were infected with HIV-1 virus (4 × 10⁵ CCID₅₀) for five days with or without GV1001 and subjected to cell viability assays.

**Determination of HIV-1 virus production.** To measure HIV-1 viral titers, HIV-1 p24 antigen capture ELISA (p24 ELISA, ABL) and RT-qPCR assay were conducted. ELISA was performed according to the manufacturer's protocol. HIV-1 RNA genomes from cell culture supernatants and pellets were purified using the QIAamp Ultrasens Virus kit (Qiagen, Hilden, Germany) and quantitated by RT-qPCR using a primer pair specific to gag of HIV-1. Glyceraldehyde phosphate dehydrogenase (GAPDH) was used as a reference gene for normalization37. The following primer pairs were used for real time qPCR: GagF, GCAGCCATGCAAATGTTAAAAGAG (sense) and GagR, TCCCCTTGTTCTCTCATACTGG (antisense); and GAPDH-F, ATTCATACCATCTCTTCCA (sense) and GAPDH-R, TGGACTTCAGCACGTACTCA (antisense). The HIV type 1 Genesig Standard kit (Primer design, Southampton, UK) was used to calibrate the viral titers.

**HIV-LTR transactivation assay.** 1G5 cells harboring an HIV-LTR luciferase reporter system were used to analyze the TAT-mediated transactivation of HIV-LTR. Cells were transfected with pSV2tat72 plasmid by electroporation or infected with HIV (1 × 10⁶ CCID₅₀) along with polybrene (final concentration: 4 μg/ml). Then, cells were treated with vehicle (DMSO), AZT or GV1001 as indicated followed by further incubation for 4 days. Cell lysates were subjected to the luciferase assay, and LTR-dependent luciferase production was analyzed using a luciferase assay kit (Promega, WI).

**Analysis of the HIV-1 reactivation and virus production.** To induce HIV reactivation from ACH-2 cells, 50 nM phorbol myristol acetate (PMA) was added to cells for 1 hour. After washing with D-PBS twice, ACH-2 cells were seeded at a concentration of 1 × 10⁶ cells/ml in 48-well plates. Increasing concentrations of AZT or GV1001 were added to cells and further incubated for 24 hours. The collected supernatants were subjected to p24 ELISA to determine the extracellular viral amounts.

**Analysis of NF-κB activation.** To investigate the effect of GV1001 on NF-κB signaling in MT-4 cells, the NF-κB luciferase assay and electromobility shift assay (EMSA) were utilized. For the NF-κB luciferase assay, MT-4 cells were transfected with NF-κB firefly luciferase plasmid together with the CMV-promoter Renilla luciferase reporter plasmid by electroporation and infected with HIV (1 × 10⁶ CCID₅₀), followed by treatment with the designated compounds. Twenty-four hours after infection, cells were harvested and subjected to the Dual-luciferase assay. For EMSA analysis, MT-4 cells (1 × 10⁵ cells) were infected with HIV (1 × 10⁵ CCID₅₀) for 1 hour and incubated with DMSO, AZT and GV1001 as indicated. Cells were harvested at 24 hours post-infection, and the nuclear fractions were extracted, followed by EMSA using the Gel Shift Assay system (Promega, Madison, WI). Briefly, NF-κB-specific oligonucleotide (5′-AGT TGA GGG GAC TTT CCC AGG C-3′) probes were radiolabeled with [γ-32P]ATP (3,000 Ci/mmol at 10 mCi/ml) and separated from unlabelled [γ-32P]ATP. In super-shift and competition assays, nuclear extract was incubated with unlabelled competitor (NF-κB oligo) and noncompetitor (AP-2 oligo, 5′-CAT GGA ACT GAC CGC CCG GCC CCC GT-3′) oligonucleotides (1.75 pmol) before adding [γ-32P]ATP-labeled NF-κB probe for 10 minutes at room temperature. Nuclear protein (10 μg) was incubated with [γ-32P]ATP-labeled NF-κB probe (20,000 cpm) for 20 minutes at room temperature and the reaction mixtures were analyzed using 6% DNA retardation gel separation and autoradiography. Activation of NF-κB was also analyzed by immunoblotting and confocal microscopy. For immunoblotting analysis, MT-4 cells and ACH-2 cells were treated with vehicle (DMSO, 0.5%), AZT (1 nM) or GV1001 (10 μM) for 24 hours, and the lysates were subjected to immunoblotting using anti-NF-κB and anti-pNF-κB (p65) antibodies. Relative band intensities were analyzed by ImageJ software. For confocal analysis, ACH-2 cells were incubated with DMSO (0.5%), AZT (1 nM) and GV1001 (10 μM) for 24 hours after stimulation with PMA (50 nM) and hTNF-alpha (30 ng/ml) for 1 hour. After fixation with 4% paraformaldehyde and permeabilization with 0.1% Triton-X-100, the cells were stained with DAPI.
with anti-NF-kB (p65) antibody and secondary Alexa Flour 594-conjugated antibody. After brief nuclear staining with DAPI, cells were observed under a laser scanning confocal microscope (Nikon A1, Japan). Scale bar, 10μm. Colocalization of p65 and DAPI was determined by Manders’ overlap coefficient analysis using NIS-Elements Ver 4.2 image software.

**Statistical analysis.** Statistical comparisons between the control and treated groups were analyzed using the Student’s t-test. The level of statistical significance was set at either p < 0.05 (*), 0.01 (**), or 0.001 (***). All experiments were independently repeated three times.

**References**

1. Vasef, M. A., Ross, J. S. & Cohen, M. B. Telomerase activity in human solid tumors. Diagnostic utility and clinical applications. *American journal of clinical pathology* 112, 568–575 (1999).

2. Kyte, J. A. Cancer vaccination with telomerase peptide GV1001. 1744–7658 (Electronic) 1354–3784 (Linking) (2009).

3. Bernhardt, S. L. et al. Telomerase peptide vaccination of patients with non-rectal pancreatic cancer: A dose escalating phase I/II study. *British journal of cancer* 95, 1474–1482, doi: 10.1038/sj.bjc.6603437 (2006).

4. Brunsvig, P. F. et al. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. *Cancer immunology, immunotherapy: CII* 55, 1553–1564, doi: 10.1007/s00262-006-0145-7 (2006).

5. Kyte, J. A. et al. Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination. *Cancer immunology, immunotherapy: CII* 58, 1609–1626, doi: 10.1007/s00262-009-0670-2 (2009).

6. Brunsvig, P. F. et al. Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial. *Clinical cancer research: an official journal of the American Association for Cancer Research* 17, 6847–6857, doi: 10.1186/0743-0330-C221-11358 (2011).

7. Greten, T. F. et al. Phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. *BMJ cancer* 109, 2007, doi: 10.1186/1471-2407–20-9 (2010).

8. Lee, S. A. et al. Heat shock protein-mediated cell penetration and cytosolic delivery of macromolecules by a telomerase-derived peptide vaccine. *Biomaterials* 34, 7495–7505, doi: 10.1016/j.biomaterials.2013.06.015 (2013).

9. Kim, B. K. et al. Tumor-suppressive effect of a telomerase-derived peptide by inhibiting hypoxia-induced HIF-1alpha-VEGF signaling axis. *Biomaterials* 35, 2924–2933, doi: 10.1016/j.biomaterials.2013.12.077 (2014).

10. Macario, A. J. & Conway de Macario, E. Sick chaperones, cellular stress, and disease. *The New England journal of medicine* 353, 1489–1501, doi: 10.1056/NEJMra0505111 (2005).

11. Wick, R. J., Jaksic, B., Buszko, M., Wick, M. C. & Grundman, C. The role of heat shock proteins in atherosclerosis. *Nature reviews. Cardiology* 11, 516–529, doi: 10.1038/nrcardi.2014.91 (2014).

12. Ishaia, J. & So, A. I. The role of heat shock proteins in bladder cancer. *Nature reviews. Urology* 10, 386–395, doi: 10.1038/nruro.2013.108 (2013).

13. Jego, G., Hazoume, A., Seigneuric, R. & Garrido, C. Targeting extracellular Hsp90 (eHsp90) as the actual target in clinical trials: intentionally or unintentionally. *International review of cell and molecular biology* 303, 203–235, doi: 10.1016/B978-0-12-407697-6.00005-2 (2013).

14. Li, W. et al. Recruitment of Hsp90 to HCV-infected cells via heat shock protein 90. *Biosensors & bioelectronics* 1823, 730–741, doi: 10.1016/j.bios.2011.09.009 (2012).

15. Geller, R., Tagawa, S. & Frydman, J. Broad action of Hsp90 as a host chaperone required for viral replication. *Biochimica et biophysica acta* 1823, 698–706, doi: 10.1016/j.bbamcr.2011.11.007 (2012).

16. Boulk, N. M. et al. Unite and differential protein signatures within the mononuclear cells of HIV-1 and HCV mono-infected and co-infected patients. *Clinical proteomics* 9, 11, doi: 10.1186/1559-0275-9.11 (2012).

17. Kingrose, J. H., Jeeninga, R. E., Berkhout, B. & Speijer, D. Proteomic studies reveal coordinated changes in T-cell expression patterns upon infection with human immunodeficiency virus type 1. *Journal of virology* 82, 4320–4330, doi: 10.1128/JVI.01819-07 (2008).

18. Vezzolo, L. et al. Gyrases B inhibitor impairs HIV-1 replication by targeting Hsp90 and the capsid protein. *The journal of biological chemistry* 285, 39314–39328, doi: 10.1074/jbc.M110.155275 (2010).

19. Anderson, I. et al. Heat shock protein 90 controls HIV-1 reactivation from latency. *Proceedings of the National Academy of Sciences of the United States of America* 111, E1528–E1537, doi: 10.1073/pnas.1302178111 (2014).

20. O’Donnell, D., Pawels, R., De Clercq, E. & Pannecoek, C. A time-of-drug addition approach to target identification of antiviral compounds. *Nature protocols* 6, 925–933, doi: 10.1038/nprot.2011.330 (2011).

21. Lee, S. A. et al. A telomerase-derived peptide regulates reactive oxygen species and hepatitis C virus RNA replication in HCV-infected cells via heat shock protein 90. *Biochemical and biophysical research communications* 471, 156–162, doi: 10.1016/j.bbrc.2016.01.160 (2016).

22. Liu, Z. & Kurtzkes, D. R. Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors. *Journal of virology* 88, 9268–9276, doi: 10.1128/JVI.00695-14 (2014).

23. Mesplede, T. & Wainberg, M. A. Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence. *Viruses* 7, 3703–3718, doi: 10.3390/v7073709 (2015).

24. Defee, M. R. et al. Extracellular Hsp90 serves as a co-factor for NF-kappaB activation and cellular pathogenesis induced by an oncogenic herpesvirus. *American journal of cancer research* 1, 687–700 (2011).

25. Hance, M. W., Nolan, K. D. & Isacs, J. S. The double-edged sword: conserved functions of extracellular hsp90 in wound healing and cancer. *Cancers* 6, 1065–1097, doi: 10.3390/cancers6061065 (2014).

26. Karn, J. The molecular biology of HIV latency: breaking and restoring the Tat-dependent transcriptional circuit. *Current opinion in AIDS & HIV* 6, 4–11, doi: 10.1097/COH.0b013e328340bb (2011).

27. Sakuragi, J., Sakuragi, S. & Shioda, T. Minimal region sufficient for genome dimerization in the human immunodeficiency virus type 1 virion and its potential roles in the early stages of viral replication. *Journal of virology* 81, 7985–7992, doi: 10.1128/jvi.00429-07 (2007).

28. Bohonowycz, J. E. et al. Extracellular Hsp90 mediates an NF-kappaB dependent inflammatory stromal program: implications for the prostate tumor microenvironment. *The Prostate* 74, 395–407, doi: 10.1002/pros.22761 (2014).

29. Chung, S. W. et al. Extracellular heat shock protein 90 induces interleukin-6 expression in vascular smooth muscle cells. *Biochemical and biophysical research communications* 378, 444–449, doi: 10.1016/j.bbrc.2008.11.063 (2009).
34. Lee, S.-A. et al. Heat shock protein-mediated cell penetration and cytosolic delivery of macromolecules by a telomerase-derived peptide vaccine. *Biomaterials* **34**, 7495–7505, doi: http://dx.doi.org/10.1016/j.biomaterials.2013.06.015 (2013).
35. Frankel, A. D. & Pabo, C. O. Cellular uptake of the tat protein from human immunodeficiency virus. *Cell* **55**, 1189–1193 (1988).
36. Schindler, M., Münch, J. & Kirchhoff, F. Human Immunodeficiency Virus Type 1 Inhibits DNA Damage-Triggered Apoptosis by a Nef-Independent Mechanism. *Journal of virology* **79**, 5489–5498, doi: 10.1128/JVI.79.9.5489-5498.2005 (2005).
37. Walker, S. R., Nelson, E. A. & Frank, D. A. STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomas. *Oncogene* **26**, 224–233, doi: 10.1038/sj.onc.1209775 (2007).
38. Bolte, S. & Cordelieres, F. P. A guided tour into subcellular colocalization analysis in light microscopy. *Journal of microscopy* **224**, 213–232, doi: 10.1111/j.1365-2818.2006.01706.x (2006).

**Acknowledgements**

This research was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (No. 2016R1A2B4011847).

**Author Contributions**

B.-J.K. and K.-S.I. designed the study. H.K. performed the experiments and wrote the draft. H.K., M.-S.C., K.-S.I. and B.-J.K. revised the manuscript.

**Additional Information**

Supplementary information accompanies this paper at http://www.nature.com/srep

**Competing financial interests:** The authors declare no competing financial interests.

**How to cite this article:** Kim, H. et al. Inhibition of HIV-1 reactivation by a telomerase-derived peptide in a HSP90-dependent manner. *Sci. Rep.* **6**, 28896; doi: 10.1038/srep28896 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/